Your Article Summary
See Latest ArticlesThe history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor
Haemophilia, 11/17/06
Négrier.C, et al. - The development of alloantibodies that inhibit the function of factor VIII (FVIII) or factor IX (FIX) is the most serious complication associated with the treatment of haemophilia. Bleeding events in patients with high-titre inhibitors generally cannot be managed with factor replacement therapy and require alternative strategies for haemostatic support
Today in Coagulation/Bleeding Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia
Blood Coagulation & Fibrinolysis, 11/03/09
The new oral anticoagulants
Blood, 11/13/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09